The estimated Net Worth of John J. Bolla is at least $11.7 Milión dollars as of 16 June 2021. Mr. Bolla owns over 2,253 units of Lantheus Inc stock worth over $10,443,758 and over the last 6 years he sold LNTH stock worth over $214,785. In addition, he makes $1,044,890 as Chief Operating Officer, Senior Vice President a Technical Operations at Lantheus Inc.
Sign up
Mr. Bolla LNTH stock SEC Form 4 insiders trading
John has made over 6 trades of the Lantheus Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 2,253 units of LNTH stock worth $54,906 on 16 June 2021.
The largest trade he's ever made was selling 2,422 units of Lantheus Inc stock on 16 June 2020 worth over $34,610. On average, John trades about 1,194 units every 81 days since 2018. As of 16 June 2021 he still owns at least 102,440 units of Lantheus Inc stock.
You can see the complete history of Mr. Bolla stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Bolla biography
John J. Bolla serves as Chief Operating Officer, Senior Vice President, Technical Operations of the Company. He is responsible for leading the company’s supply chain, manufacturing, operations, engineering and facilities functions. He brings to the role more than 23 years of diverse supply chain, operations and manufacturing experience in the pharmaceutical industry. Prior to joining Lantheus, Mr. Bolla spent 20 years at GlaxoSmithKline plc (“GSK”), a global branded pharmaceutical company. He held various senior leadership roles, including Vice President, Supply Chain, North America, where he was responsible for leading all manufacturing, supply planning, logistics and distribution for GSK’s largest global market. He also held senior roles as Vice President and Site General Manager for a large GSK manufacturing facility in the U.S., as well as Vice President and Global Head of External Supply and Global Contract Manufacturing. He has also served in multiple senior Procurement leadership roles at GSK. Mr. Bolla holds a Bachelor of Science in Business Administration/Accounting from The University of Central Florida.
What is the salary of John Bolla?
As the Chief Operating Officer, Senior Vice President a Technical Operations of Lantheus Inc, the total compensation of John Bolla at Lantheus Inc is $1,044,890. There are 4 executives at Lantheus Inc getting paid more, with Mary Heino having the highest compensation of $4,320,910.
How old is John Bolla?
John Bolla is 50, he's been the Chief Operating Officer, Senior Vice President a Technical Operations of Lantheus Inc since 2019. There are 19 older and 7 younger executives at Lantheus Inc. The oldest executive at Lantheus Holdings Inc is James Thrall, 76, who is the Independent Director.
What's John Bolla's mailing address?
John's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA, MA, 01862.
Insiders trading at Lantheus Inc
Over the last 9 years, insiders at Lantheus Inc have traded over $500,725,766 worth of Lantheus Inc stock and bought 8,000 units worth $141,200 . The most active insiders traders include David F Burgstahler, Capital Partners Gp, Llc Av... a Sriram Venkataraman. On average, Lantheus Inc executives and independent directors trade stock every 11 days with the average trade being worth of $15,777,680. The most recent stock trade was executed by James H Thrall on 21 August 2024, trading 1,000 units of LNTH stock currently worth $98,520.
What does Lantheus Inc do?
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
What does Lantheus Inc's logo look like?
Complete history of Mr. Bolla stock trades at Lantheus Inc
Lantheus Inc executives and stock owners
Lantheus Inc executives and other stock owners filed with the SEC include:
-
Mary Heino,
President, Chief Executive Officer, Director -
Robert Marshall,
Chief Financial Officer, Treasurer -
Mary Anne Heino,
CEO, Pres & Director -
Michael Duffy,
Senior Vice President, Law and Public Policy and General Counsel -
John Bolla,
Chief Operating Officer, Senior Vice President, Technical Operations -
Simon Robinson,
Senior Vice President - Research and Pharmaceutical Development -
Robert J. Marshall Jr., CFA,
CFO & Treasurer -
Paul M. Blanchfield,
Chief Operating Officer -
Daniel M. Niedzwiecki,
Sr. VP, Gen. Counsel & Corp. Sec. -
Brian Markison,
Non-Executive Independent Chairman of the board -
Samuel Leno,
Independent Director -
Frederick Robertson,
Independent Director -
James Clemmer,
Independent Director -
Gary Pruden,
Independent Director -
Julie McHugh,
Independent Director -
James Thrall,
Independent Director -
Heinz Maeusli,
Independent Director -
Gerard Ber,
Independent Director -
Istvan Molnar,
Chief Medical Officer -
Paul Blanchfield,
Chief Commercial Officer -
Carol Walker,
Senior Vice President - Quality -
Etienne Montagut,
Senior Vice President - Corporate Development -
Etienne Montagut,
Chief Bus. Officer -
Carol Walker,
Sr. VP of Quality -
Ying Yao,
Chief HR Officer -
Melissa Downs,
Director of Corp. Communications -
Linda S. Lennox,
VP of Corp. Communications & Chief of Staff -
Mark Richard Kinarney,
Sr. Director of Investor Relations -
Andrea Sabens,
Principal Accounting Officer -
Capital Partners Gp, Llc Av...,
-
David F Burgstahler,
Director -
Cesare Orlandi,
Chief Medical Officer -
Derace L Schaffer,
Director -
Sriram Venkataraman,
Director -
Timothy G Healey,
SVP, Commercial -
Daniel Niedzwiecki,
See Remarks -
Ying Vivian Yao,
Chief Human Resources Officer -
Minnie Baylor Henry,
-
Andrea Sabens,
Chief Accounting Officer -
Kenneth Pucel,
Director -
John W. Crowley,
VP Finance and Accounting -
John K Bakewell,
CFO and Treasurer -
Patrick O'neill,
Director -
William C. Jr. Dawes,
VP Mfrg and Operations -
Jeffrey Allen Bailey,
CEO and President -
Kimberly Brown,
Chief Accounting Officer -
Jeffrey Humphrey,
Chief Medical Officer -
Sam R Leno,
-
Jean Claude Provost,
Chief Medical Officer